← Back to Search

Recombinant Protein

INBRX-101/rhAAT-Fc for Alpha-1 Antitrypsin Deficiency (rhAAT-Fc Trial)

Phase 1
Waitlist Available
Research Sponsored by Inhibrx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 7 months
Awards & highlights

rhAAT-Fc Trial Summary

This study is evaluating whether a drug which is designed to help the body produce a protein which is lacking in people with a rare disease may be safe and effective.

Eligible Conditions
  • Alpha-1 Antitrypsin Deficiency

rhAAT-Fc Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 7 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 7 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Frequency of adverse events of INBRX-101
Severity of adverse events of INBRX-101
Secondary outcome measures
Serum
Bronchoalveolar Lavage
Serum
+5 more

rhAAT-Fc Trial Design

2Treatment groups
Experimental Treatment
Group I: Part 2 Multiple Ascending DoseExperimental Treatment1 Intervention
INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).
Group II: Part 1 Single Ascending DoseExperimental Treatment1 Intervention
INBRX-101 will be escalated in subjects with alpha-1 antitrypsin deficiency (AATD).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
INBRX-101/rhAAT-Fc
2019
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

Inhibrx, Inc.Lead Sponsor
8 Previous Clinical Trials
1,716 Total Patients Enrolled
Klaus Wagner, MD, PhDStudy DirectorCMO
2 Previous Clinical Trials
450 Total Patients Enrolled
Klaus Wagner, MD PhDStudy DirectorInhibrx, Inc.
1 Previous Clinical Trials
201 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
2019. "Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03815396.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top